INTRODUCTION Description of the condition
Migraine is a prevalent neurovascular headache disorder, which is characterised by recurrent attacks of unilateral pulsating moderate-to-severe headaches. The headaches usually last 4-72 h and have concomitant symptoms such as light and sound sensitivity, nausea and vomiting. Migraine can be triggered by food, environment and mental factors, and may be aggravated by routine physical activity. Symptoms usually start at puberty and have two major subtypes: migraine with aura and migraine without aura. The former is characterised by visual, sensory or central nervous system symptoms before the onset of headache and associated migraine symptoms, while the latter does not have the premonitory symptomatology. 1 The pathophysiology of migraine is still widely debated. [2] [3] [4] The prevailing view is that the activation and sensitisation of trigeminovascular meningeal nociceptors start the headache phase of migraine. Then the second-order and third-order central trigeminovascular neurons are activated, which in turn activate different areas of the brain stem and forebrain, resulting in pain and other accompanying migrainous symptoms. 4 Population-based surveys have shown that migraine occurs in at least one in every seven adults worldwide, 5 and affects women threefold more than men. 6 In the Global Burden of Disease Survey 2010, migraine was ranked as the third most prevalent disorder and seventh highest specific cause of disability worldwide. 7 Migraine seriously impacts the patient's health and quality of life, and is often a source of great disability, with migraineurs' normal activities limited up to 78% during migraine attacks. 8 Patients with migraine may also be afflicted with fear in the period between episodes of headache attack. 9 Meanwhile, the consequent economic burden of migraine is enormous. 10 11 A research based on the American Migraine Prevalence and Prevention (AMPP) Study showed that the average annual direct cost per person of episodic migraine was $1757 in the USA. 12 A cross-sectional survey in eight European Union countries representing 55% of the adult population has estimated a mean annual cost of migraine per person of €1222 and a total annual cost of €111 billion for adults aged 18-65 years. 13 An association between migraine and cardiovascular and cerebrovascular diseases has also been shown by numerous studies.
14 A systematic review of studies investigating migraine and cardiovascular disease (n=25) found that the risk of ischaemic stroke was doubled in people who had migraine with aura. 15 Description of the intervention Acupuncture plays an important role in traditional Chinese medicine with a history of thousands of years. It treats disease by inserting needles along specific pathways or meridians. Acupuncture is utilised worldwide to treat headache, including migraine. [16] [17] [18] [19] [20] [21] [22] Of patients in the USA who accept acupuncture as a valid treatment, 9.9% said that they had been treated with acupuncture for migraine or other headaches. 23 In 1998, acupuncture was suggested as an adjunct or an alternative treatment for headache by the National Institutes of Health (NIH). 24 It was also suggested by the China Association for the Study Pain (CASP) as a complementary and alternative treatment for migraine. 25 26 Potential therapeutic mechanisms of acupuncture in migraine Some theories may explain the mechanism of acupuncture in headache relief. Studies suggested that acupuncture could inhibit pain transmission to the central nervous system by stimulating different types of afferent fibres (eg, Aβ, Aδ). 27 Acupuncture was also found to be able to facilitate the release of some pain suppressors including endorphins, which are opiate chemical substances, within the central nervous system. 28 29 Justification and significance of the review For the treatment of migraine, the European Federation of Neurological Societies (EFNS) recommended treatment addressing acute attacks as well as prophylaxis. 30 Typical treatments for acute migraine include analgesics, non-steroidal anti-inflammatory drugs and triptans. 26 Triptans account for almost 80% of antimigraine analgesics. 31 However, about one-third of patients with migraine using triptans did not get headache relief at 2 h after taking medication, and over half were willing to try other treatments. 26 32 33 There are unmet needs in acute migraine treatment. 34 35 Acupuncture has been used for both migraine attacks and prevention. A Cochrane systematic review published in 2009 concluded that acupuncture was at least as effective as, or possibly more effective than, preventive drug treatment for migraine prophylaxis with fewer side effects compared with conventional treatments. 36 However, there is a lack of adequately powered evidence to prove the effect and safety of acupuncture for acute migraine attacks in adults.
Objectives
This systematic review aims to assess if acupuncture is effective and safe in relieving headache, preventing relapse and reducing migraine-associated symptoms for the treatment of acute migraine attacks in adults. The following comparisons will be addressed: 1. Acupuncture versus sham acupuncture, placebo or no treatment. 2. Acupuncture versus pharmacological therapies.
METHODS AND ANALYSIS Types of studies
We will include randomised controlled trials (RCTs) using acupuncture to treat a migraine headache episode. Quasi-RCTs will be excluded. The first period of randomised cross-over trials will be included.
Types of participants
Adults diagnosed with migraine (according to the definition of the Headache Classification Subcommittee of the International Headache Society) will be eligible for inclusion. Studies where participants are receiving stable migraine prophylactic treatment will be included. There will be no restrictions on migraine type (eg, migraine with aura, migraine without aura), duration of migraine, frequency of attack or pain intensity.
Types of intervention
Interventions in the treatment group will include manual acupuncture, electroacupuncture, scalp acupuncture, auricular acupuncture, eye acupuncture, fire needling, warm needling and elongated needling. There will be no duration restrictions on the intervention. Comparison interventions include sham acupuncture, placebo, no treatment or pharmacological therapies. Trials evaluating acupuncture plus another treatment versus the same other treatment alone will be included. Those trials comparing different forms of acupuncture and those evaluating prophylaxis effect will be excluded.
Types of outcome measures
Primary outcomes Pain-free ( pain score=0) at 2 h after the treatment, without the use of rescue medication. 37 Study data from scales measuring pain intensity as an outcome will be included, such as the visual analogue scale, Numerical Rating Scale (NRS), Verbal Rating Scale (VRS). 37 38 Secondary outcomes 1. Headache relief (a decrease in headache from severe or moderate to none or mild within 2 h, before any rescue medication). 2. Sustained pain freedom ( pain free at 2 h with no use of rescue medication or relapse within the subsequent 46 h). 3. After 2 h pain freedom, any headache pain from 2 to 48 h after study drug administration, regardless of its severity, is considered a relapse or recurrence. 4. Incidence of relapse (recurrence). 5. Adverse events. 6. Migraine-associated symptoms (nausea, photophobia, phonophobia). This search strategy will be modified as required for other electronic databases.
Search methods for identification of studies

Other sources
The reference lists of retrieved articles and related conference proceedings will also be searched for any relevant RCTs that were not identified during the database searches.
Data collection and analysis
Selection of studies
Prior to the selection of the studies, a consensus on screening and later procedures will be developed by discussion among all reviewers. Literature search results will be uploaded to a database set up by EndNote software (V.X6). The screening of studies will be carried out by two independent reviewers (RD and XL). Reviewers will read the titles, abstracts and full texts (if necessary) of the search results to select studies suitable for inclusion. Results of each reviewer will be compared to determine final eligibility, with discrepancy resolved via discussion with a third reviewer (ZL). The study screening process is shown in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart (figure 1).
Data extraction and management
Using a data extraction form (Excel), reviewers will extract information on the author, year of publication, country, participant characteristics, methods, interventions and outcomes, and adverse events. Data will be cross-checked between reviewers (RD and XL) with discrepancies resolved with discussion. For unresolved discrepancies, final determination from a third reviewer will be sought (ZL). Additional information from corresponding authors of the included studies will be requested in circumstances where the published data are unclear, contain errors, are missing or require further clarification.
Assessment of risk of bias
Two independent reviewers (RD and XL) will assess the risk of bias for each included RCT using the Cochrane Collaboration's 'Risk of bias' tool. 39 Study bias will be classified as either: 'unclear', 'low' or 'high' risk for the following criteria: random sequence generation, allocation concealment, blinding, incomplete data, selective outcome reporting and other bias. Discrepancies in the ratings between the primary reviewers will be resolved by discussion with a third reviewer (ZL). We will compute graphic representations of potential bias within and across studies using RevMan V.5.3.5.
Measures of treatment effect
For dichotomous outcomes, data will be analysed using the risk ratio with 95% CIs. For continuous outcomes, the weighted mean difference (WMD) or the standard mean difference (SMD) with 95% CI will be used. If the same measurement scales are used, WMD analyses will be performed; otherwise, SMD will be used.
Unit of analysis issues
The unit of analysis will be the individual participant.
Dealing with missing data
If necessary data are missing, we will try to get the information by contacting the first or corresponding authors of the included studies. If the missing data cannot be obtained, we will analyse the available data. When possible, a sensitivity analysis will be conducted to address the potential impact of missing data. 
Assessment of heterogeneity
The Q statistic from the χ 2 test and the I 2 value will be used to quantify statistical heterogeneity. According to the Cochrane Handbook, Q is considered statistically significant if p<0.10. The I 2 value is classified into four categories: 0-40% indicates little or no heterogeneity; 30-60% indicates moderate heterogeneity; 50-90% indicates substantial heterogeneity and 75-100% indicates considerable heterogeneity.
Assessment of reporting biases
If there are at least 10 included trials, funnel plots will be generated to estimate reporting biases.
Data synthesis
Data synthesis will be conducted using Review Manager (V.5.3.5) from the Cochrane Collaboration. If the heterogeneity test shows little or no heterogeneity, the fixed effect model will be used for pooled data. The random effect model will be adopted if statistical heterogeneity is observed (I 2 ≥50%). If there is considerable variation in results, and particularly if there is inconsistency in the direction of effect, then the meta-analysis will not be performed; a narrative, qualitative summary will be provided. 39 
Subgroup analysis
Subgroup analysis can explore and assess the heterogeneity. If the data are available, we will conduct subgroup analysis according to different types of acupuncture therapies.
Sensitivity analysis
Sensitivity analysis can assess the stability and reliability of the analysis results and restrict analysis to a low risk of bias. The analysis will be repeated by removing the impact of lower quality studies, inputting missing data or choosing a different method of meta-analysis. 
Summary of evidence
We will assess the quality of evidence for all outcomes using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. 39 The following factors will be considered: limitations in the design and implementation of available studies suggesting a high likelihood of bias, indirectness of evidence, unexplained heterogeneity or inconsistency of results, imprecision of results and high probability of publication bias. The quality of evidence will be adjudicated into four levels: high, moderate, low and very low quality.
DISCUSSION
This systematic review will evaluate published RCT evidence for the effectiveness and safety of acupuncture for acute migraine attacks in adults. In addition, it may assist clinician clinical treatment for migraine with potential to influence future recommendations of treatment guidelines. The proposed review is limited to English and Chinese publications. This limitation may reduce the significance of the review's results and any subsequent conclusions that may be formed. If we need to amend this protocol, we will give the date of each amendment, a description of the change and the rationale.
